Shuta Ohara

947 total citations · 1 hit paper
37 papers, 627 citations indexed

About

Shuta Ohara is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Shuta Ohara has authored 37 papers receiving a total of 627 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Shuta Ohara's work include Lung Cancer Treatments and Mutations (31 papers), HER2/EGFR in Cancer Research (7 papers) and Lung Cancer Research Studies (6 papers). Shuta Ohara is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), HER2/EGFR in Cancer Research (7 papers) and Lung Cancer Research Studies (6 papers). Shuta Ohara collaborates with scholars based in Japan, United States and Austria. Shuta Ohara's co-authors include Tetsuya Mitsudomi, Toshio Fujino, Kenichi Suda, T. Koga, Masaki Shimoji, Masaya Nishino, Toshiki Takemoto, Masato Chiba, Junichi Soh and Akira Hamada and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Hematology & Oncology and Cells.

In The Last Decade

Shuta Ohara

32 papers receiving 614 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

2021 167 citations T. Koga, Kenichi Suda et al. Journal of Thoracic Oncology profile →

Peers

Shuta Ohara

PRM

ONCOL

PFM

Masaya Nishino Japan

Shinji Nakamichi Japan

Magda Bahcall United States

Osvaldo Rudy Aren Chile

N. B. Leighl United States

K. Park South Korea

Toshiki Takemoto Japan

Jang Ho Cho South Korea

Inna Khodos United States

C. Ligorio Italy

Masaya Nishino Japan

Shuta Ohara

404 ×1.0

PRM

299 ×0.9

ONCOL

301 ×1.0

99 ×0.9

61 ×0.9

PFM

Citations per year, relative to Shuta Ohara Shuta Ohara (= 1×) peers Masaya Nishino

Countries citing papers authored by Shuta Ohara

Since Specialization

Citations

This map shows the geographic impact of Shuta Ohara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuta Ohara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuta Ohara more than expected).

Fields of papers citing papers by Shuta Ohara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuta Ohara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuta Ohara. The network helps show where Shuta Ohara may publish in the future.

Co-authorship network of co-authors of Shuta Ohara

This figure shows the co-authorship network connecting the top 25 collaborators of Shuta Ohara. A scholar is included among the top collaborators of Shuta Ohara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuta Ohara. Shuta Ohara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suda, Kenichi, Akira Hamada, Toshio Fujino, et al.. (2025). Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations—An In Vitro Study. Cells. 14(17). 1386–1386.

Suda, Kenichi, Akira Hamada, Shuta Ohara, et al.. (2024). Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study. Biomedicines. 12(7). 1412–1412. 6 indexed citations

Ohara, Shuta, Kenichi Suda, Akira Hamada, et al.. (2024). Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer. Thoracic Cancer. 15(31). 2229–2234. 1 indexed citations

Sakai, Kazuko, Shuta Ohara, Junko Tanaka, et al.. (2024). Improved platelet separation performance from whole blood using an acoustic fluidics system. Cancer Science. 115(11). 3795–3803. 1 indexed citations

Hamada, Akira, Kenichi Suda, Masaya Nishino, et al.. (2023). Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion. Journal of Thoracic Oncology. 19(1). 71–79. 9 indexed citations

Koga, T., Junichi Soh, Akira Hamada, et al.. (2023). Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing. JTO Clinical and Research Reports. 4(9). 100554–100554. 4 indexed citations

Hamada, Akira, Kenichi Suda, Toshio Fujino, et al.. (2022). Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC. JTO Clinical and Research Reports. 3(5). 100321–100321. 7 indexed citations

Ohara, Shuta, Kenichi Suda, Toshio Fujino, et al.. (2021). Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. Lung Cancer. 154. 84–91. 10 indexed citations

Fujino, Toshio, Kenichi Suda, Kazuko Sakai, et al.. (2021). Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas. Clinical Lung Cancer. 23(3). e185–e195. 1 indexed citations

10.

Takemoto, Toshiki, Junichi Soh, Shuta Ohara, et al.. (2021). The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery. Surgery Today. 51(9). 1480–1487. 7 indexed citations

11.

Koga, T., Kenichi Suda, Masaya Nishino, et al.. (2021). Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. Translational Lung Cancer Research. 10(8). 3659–3670. 10 indexed citations

12.

Koga, T., Kenichi Suda, Toshio Fujino, et al.. (2021). KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. Journal of Thoracic Oncology. 16(8). 1321–1332. 167 indexed citations breakdown →

13.

Suda, Kenichi, Kazuko Sakai, Keiko Obata, et al.. (2020). Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non–Small Cell Lung Cancers: Analysis of Five Cases. Clinical Lung Cancer. 22(2). e141–e145. 7 indexed citations

14.

Suda, Kenichi, Isao Murakami, Keiko Obata, et al.. (2020). Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. Lung Cancer. 148. 100–104. 6 indexed citations

15.

Ohara, Shuta, Kenichi Suda, Kenji Tomizawa, et al.. (2020). Prognostic value of plasma fibrinogen and d-dimer levels in patients with surgically resected non-small cell lung cancer. Surgery Today. 50(11). 1427–1433. 15 indexed citations

16.

Ohara, Shuta, Kenji Tomizawa, Shigeki Shimizu, et al.. (2019). Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis. SHILAP Revista de lepidopterología. 5(1). 105–105.

17.

Fujino, Toshio, Yoshihisa Kobayashi, Kenichi Suda, et al.. (2019). Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. Journal of Thoracic Oncology. 14(10). 1753–1765. 114 indexed citations

18.

Koga, T., Kenichi Suda, Masaya Nishino, et al.. (2019). P2.03-20 Potent in Vitro Activity of Tarloxotinib for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance. Journal of Thoracic Oncology. 14(10). S690–S691. 4 indexed citations

19.

Fujino, Toshio, Kenichi Suda, Yoshihisa Kobayashi, et al.. (2018). P1.13-41 In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping. Journal of Thoracic Oncology. 13(10). S598–S598. 1 indexed citations

20.

Tomizawa, Kenji, Shigeki Shimizu, Shuta Ohara, et al.. (2017). Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. Lung Cancer. 112. 57–61. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact